A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

Part of paid clinical trials in Los Angeles, California.

Sponsor
ArriVent BioPharma, Inc.
Study ID
NCT07066657
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • MRG007 — DRUG
    MRG007 will be administrated as specified in the protocol.

Study Details

This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.

Key Dates

Start date
Jul 25, 2025
Status verified
Jun 2026
Primary completion
May 31, 2029
Completion
Dec 31, 2030

Study Design

Enrollment
405 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: MRG007

Primary Outcome Measure

Dose Limiting Toxicity (DLT) - Phase Ia [ Time Frame: Baseline to Day 21 of the first treatment cycle ]

Central Contacts

Locations (10)

FacilityCityStateZIPSite coordinators
ULCALos AngelesCalifornia90095-
UCSFSan FranciscoCalifornia94158-
University of ColoradoAuroraColorado80010-
Sarah Cannon Research InstituteDenverColorado80218-
Sarah Cannon Research InstituteSarasotaFlorida34232-
Sarah Cannon Research InstituteNashvilleTennessee37203-
MD Anderson Cancer CenterHoustonTexas77030-
NEXT DallasIrvingTexas75039-
NEXT VirginiaFairfaxVirginia22031-
Fred Hutchinson Cancer CenterSeattleWashington98109-

Find similar trials in Los Angeles, CA

By condition
Colorectal cancerGastric cancerPancreatic cancer
By specialty
OncologyGI oncology
By research site
ULCA· Los Angeles, CAUCSF· San Francisco, CAUniversity of Colorado· Aurora, COSarah Cannon Research Institute· Denver, COSarah Cannon Research Institute· Sarasota, FLSarah Cannon Research Institute· Nashville, TN

Related Studies